Navigation Links
Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit
Date:8/1/2014

s future financial condition, operating results, strategy and plans;
  • the effects of governmental regulation on our business or potential business combination transactions;
  • the ability to obtain regulatory approvals and meet other conditions to the offer, including the necessary stockholder approval, on a timely basis;
  • Valeant's ability to sustain and grow revenues and cash flow from operations in our markets and to maintain and grow our customer base, the need for innovation and the related capital expenditures and the unpredictable economic conditions in the United States and other markets;
  • the impact of competition from other market participants;
  • the development and commercialization of new products;
  • the availability and access, in general, of funds to meet our debt obligations prior to or when they become due and to fund our operations and necessary capital expenditures, either through (i) cash on hand, (ii) free cash flow, or (iii) access to the capital or credit markets;
  • our ability to comply with all covenants in our indentures and credit facilities, any violation of which, if not cured in a timely manner, could trigger a default of our other obligations under cross-default provisions; and
  • the risks and uncertainties detailed by Allergan with respect to its business as described in its reports and documents filed with the SEC.
  • All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement.  Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof.  Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this communication or to reflect actual outcomes.

    ADDITION
    '/>"/>

    SOURCE Valeant Pharmaceuticals International, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
    2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
    3. Valeant Pharmaceuticals To Host Investor Day
    4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
    5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
    6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
    7. Valeant Pharmaceuticals Announces Management Change
    8. Valeant Pharmaceuticals To Syndicate Incremental Loans
    9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
    10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
    11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/2/2014)... Oct. 2, 2014  Perrigo Company plc (NYSE: ... laws of Ireland (the " Company ... (the "Exchange Offer") up to $500,000,000 of its new 1.30% ... $600,000,000 of its new 2.30% Senior Notes due 2018 (the ... Senior Notes due 2023 (the " 2023 Exchange Notes ") ...
    (Date:10/2/2014)...   Softworld, Inc. announced today the launch of ... on the specific needs of pharmaceutical, biotech, and medical ... been highly successful in the clinical domain, the team ... the quality, regulatory, and validation space. ... the current Biometric team and the newly created Life ...
    (Date:10/2/2014)... , Oct. 2, 2014  Isis Pharmaceuticals, ... following webcast:What: , Webcast and conference call to ... 2 clinical studies of ISIS-SMN Rx in ... which will be presented on the morning (CEST) ... World Muscle Society in Berlin, GermanyWhen:Friday, October 10 ...
    Breaking Medicine Technology:Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 4Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress 2
    ... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting ... Arizona on Wednesday, November 11, 2009 at 10:00 a.m. PT ... of finance and chief financial officer at Amylin Pharmaceuticals, will ... the presentation will be webcast and a recording will be ...
    ... N.J., Nov. 5 CANTEL MEDICAL CORP. (NYSE: ... & CEO, will be presenting at the Sidoti & Company, ... is scheduled for 9:05 AM ET on Friday, November 20, ... & A session immediately following the presentation. In addition, Mr. ...
    Cached Medicine Technology:
    (Date:10/2/2014)... (HealthDay News) -- Scientists have pinpointed a molecule that ... colds. The researchers say this finding could offer ... treat these attacks. Most asthma attacks (80 percent ... the airways, according to the British researchers. Most of ... the common cold. The researchers found that a ...
    (Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... reduced by breast-feeding. Nor will delaying the introduction of a ... help prevent celiac disease. Those are the conclusions ... New England Journal of Medicine . The new ... celiac disease if mothers breast-feed their babies and introduce gluten ...
    (Date:10/2/2014)... discovery by scientists at The University of Nottingham could ... of painkiller. , A drug resulting from the research, ... would offer new hope to sufferers of chronic pain ... effective painkillers are currently available. , The work, led ... Life Sciences, in collaboration with David Bates, Professor of ...
    (Date:10/1/2014)... Journal of the American Medical Association shows ... or severe chronic knee pain, acupuncture did not provide ... randomly assigned 282 patients (50 years or older) with ... pretend laser treatment. , Treatments were delivered for ... and sham (inactive) laser acupuncture. , Researcher Professor Kim ...
    (Date:10/1/2014)... 1, 2014) Despite a policy focus on ... disabilities, this vulnerable population continues to have significant ... The Journal of the American Dental Association , ... Tufts University School of Dental Medicine report on ... at-home oral care provided by caregivers to adults ...
    Breaking Medicine News(10 mins):Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Medical discovery first step on path to new painkillers 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3
    ... ask their physician will you be delivering my baby" ... to determine whether obstetric outcomes differed between women whose ... attended by an on-call obstetrician who did not provide ... live single term births between 1991 and 2001 at ...
    ... Aug. 21 issue of the Journal of the American ... found that people with a larger waist-to-hip ratio may ... evaluates the association between different measures of obesity and ... people who develop fat around the middle have more ...
    ... Spirometry testing is a widely accepted and encouraged diagnostic ... research shows that it is not used nearly enough. ... the peer-reviewed journal of the American College of Chest ... with a COPD diagnosis ever received spirometry testing. ...
    ... to prevent cluster headaches can cause heart problems, according ... issue of Neurology, the medical journal of the American ... cluster headaches should be closely monitored with frequent electrocardiograms ... headache is a rare, severe form of headache that ...
    ... individually or in combination, do not appear to reduce ... at high risk for heart disease, according to a ... Internal Medicine, one of the JAMA/Archives journals. , Oxidative ... to the development of cardiovascular disease, according to background ...
    ... and may produce beneficial changes in the brains and ... an article posted online today that will appear in ... one of the JAMA/Archives journals. , In patients with ... sheaths that protect nerve cells in the brain and ...
    Cached Medicine News:Health News:Waist-to-hip ratio may better predict cardiovascular risk than body mass index 2Health News:Study says COPD testing is not measuring up 2Health News:Drug for cluster headaches may cause heart problems 2Health News:Antioxidants show no clear benefit against cardiovascular events, death in high-risk women 2Health News:DNA vaccine against multiple sclerosis appears safe, potentially beneficial 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: